Sino Biopharmaceutical Limited

HKSE:1177.HK

Sector

🏥 Health Care

Industries

💊 Drugstores & Retail Pharmacies

🔬 Clinical Trials

💊 Pharmaceuticals

Location

Hong Kong

Market Cap

USD 11.97 B

Share Price

USD 0.67

Avg Daily Volume

109,770,568

Change (1 day)

1.78%

Change (1 year)

100.92%

Change (YTD)

62.43%

Sino Biopharmaceutical Limited Accounts Payable for the year ending December 31, 2024: USD 205.09 M

Sino Biopharmaceutical Limited Accounts Payable is USD 205.09 M for the year ending December 31, 2024, a 9.10% change year over year. Accounts payable are amounts owed by the company to suppliers or vendors for goods or services received but not yet paid.

Sino Biopharmaceutical Limited Accounts Payable for the year ending December 31, 2023 was USD 187.99 M, a -31.13% change year over year.
Sino Biopharmaceutical Limited Accounts Payable for the year ending December 31, 2022 was USD 272.98 M, a -3.35% change year over year.
Sino Biopharmaceutical Limited Accounts Payable for the year ending December 31, 2021 was USD 282.45 M, a -5.35% change year over year.
Sino Biopharmaceutical Limited Accounts Payable for the year ending December 31, 2020 was USD 298.40 M, a 14.84% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Accounts Payable	Short-Term Debt	Long-Term Debt	Total Liabilities

HKSE: 1177.HK

Sino Biopharmaceutical Limited

CEO	Mr. S. Y. Tse
IPO Date	Dec. 8, 2003
Location	Hong Kong
Headquarters	Office Tower
Employees	24,379
Sector	🏥 Health Care
Industries Drugstores & Retail Pharmacies 🔬 Clinical Trials 💊 Pharmaceuticals

Description

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.